Hereditary Hemorrhagic Telangiectasia: Clinical Presentation
HHT typically presents with recurrent spontaneous epistaxis (nosebleeds) occurring in over 90% of patients, along with characteristic mucocutaneous telangiectasias appearing as red spots on the lips, tongue, fingers, and nasal mucosa, plus visceral arteriovenous malformations affecting the lungs, liver, brain, and gastrointestinal tract 1, 2, 3.
Core Clinical Features
The presentation follows an age-related pattern of symptom expression 1:
Early Manifestations
- Epistaxis begins in childhood and is nearly universal, with patients averaging up to 18 bleeds per month 4
- Nosebleeds can last hours per day and cause significant psychosocial morbidity, social isolation, and employment difficulties 2
- Most patients exhibit symptoms by age 60, with 97% penetrance 5
Progressive Features
Mucocutaneous telangiectasias develop over time on:
Visceral arteriovenous malformations in:
Clinical Consequences
Bleeding-Related Complications
- Iron deficiency anemia develops in nearly 50% of patients from chronic blood loss 3
- Gastrointestinal bleeding ranges from minor to life-threatening 6
- Chronic bleeding causes physical and emotional distress 7
Shunt-Related Complications
- Complications from arteriovenous shunting through malformations 1
- Pulmonary AVMs can lead to paradoxical emboli, stroke, or brain abscess
- Hepatic VMs can cause high-output cardiac failure
Thrombotic Complications
- Increased venous thromboembolism risk, particularly in patients over 65 years (incidence 45.1/1,000 patient-years vs 11.6/1,000 in younger patients) 8
- Cerebral hemorrhage and thrombotic events increase morbidity and mortality 5
Diagnostic Criteria
Use the Curaçao criteria (upheld in international guidelines) 1:
- Spontaneous recurrent epistaxis
- Multiple telangiectasias at characteristic sites
- Visceral arteriovenous malformations
- First-degree family member with HHT
Definite diagnosis requires 3 of 4 criteria; possible diagnosis with 2 criteria 9.
Critical Pitfall: Atypical Presentations
Do not exclude HHT based solely on absence of epistaxis 5. While epistaxis occurs in >90% of cases, rare patients remain asymptomatic until late adulthood and present first with:
- Spontaneous intracranial hemorrhage (subdural hematomas)
- Unexplained gastrointestinal bleeding
- Unexplained iron-deficiency anemia
- Complications from visceral AVMs
One documented case showed a patient remaining asymptomatic until age 67, presenting with bilateral subdural hematomas and GI bleeding without prior epistaxis 5. Overreliance on classic mucocutaneous features contributes to diagnostic delay 5.
Genetic Basis
97% of patients with definite clinical diagnosis have identifiable mutations in 1:
- ENG gene (HHT type 1)
- ACVRL1 gene (HHT type 2)
- SMAD4 gene (juvenile polyposis-HHT overlap syndrome)
Key Clinical Points
- HHT is significantly underdiagnosed with long diagnostic delays 1
- Prevalence is approximately 1 in 5,000 1, 2
- Autosomal dominant inheritance pattern 1
- Screen first-degree family members once diagnosis is established 6
- Disease manifestations are more commonly associated with significant morbidity rather than mortality 4